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Summary
In no other field of biomedicine has such revolutionary
change taken place in recent decades as it has in molecular
genetics. The accumulated knowledge in this field will not
only enable clinicians to make new treatment decisions in
future, but will also help to save on healthcare costs. A
positive test result will be the prerequisite for carrying out
targeted drug treatment (companion diagnostics). Specific
molecular diagnostics provide doctors with additional in-
formation that was not previously available, enabling them
to optimise treatment accordingly. At the same time, pro-
gnostic tests mean that targeted preventive measures can
be taken. Highly informative non-invasive tests will enable
early detection and prevention to play a greater role. Tech-
nological breakthroughs, such as high-throughput sequen-
cing, will lead to a flood of data in the future. The challenge
lies in the quality of interpretation, which means extracting
useful information for doctor and patient.
Unlike data collection, interpretation is complex and ex-
pensive: it requires a high degree of expertise and a lot of
resources. At the same time, experts stress that – as well as
improvements in the accuracy and speed of data analysis
– defined quality criteria must be generated for reliable in-
terpretation of results. These challenges need to be tackled
so that the population can benefit to the utmost from the
opportunities offered by these developments: rapidly avail-
able and informative tests for targeted therapies based on
high-quality data.
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Introduction
In recent years the opportunities for collecting individual
genetic data have expanded dramatically. Technological
advances in high-throughput sequencing of genetic ma-
terial (including next generation sequencing [NGS]), im-
provements in microarrays and the steadily falling costs of
performing such tests are among the factors that have con-
tributed to this expansion. Today this opens up a whole
range of genetic testing possibilities and provides a far
more detailed view of the human genome through to its
complete sequencing. The “omics era” (genomics, proteo-
mics, transcriptomics, etc.) has definitely arrived.
These technological advances give rise to new opportun-
ities, but also pose certain challenges. Examples of these
opportunities include better and faster diagnoses, informat-
ive tests that are non-invasive (such as novel prenatal tests
on maternal blood) or a reduction of side effects caused
by drug treatments (companion diagnostics). Major chal-
lenges lie in the interpretation of data, a partial lack of
counselling and education of patients, in quality assurance
or data security [1]. These factors are particularly evident
in so-called direct-to-consumer (DTC) tests, which mean
genetic tests that are accessible to all on the internet (in
Switzerland DTC tests with medical implications are at
present banned).
Challenges posed by direct-to-
consumer tests
The challenge posed by DTC tests lies in the fact that
they can be lifestyle products, for instance when they claim
they can find someone’s genetically “right” partner, cal-
culate a person’s IQ or when they involve ancestry re-
search. However, they can also deliver relevant medical
data, for example information about monogenetic diseases
such as cystic fibrosis for which there is complete pen-
etrance. Hence a broad range of tests of variable signific-
ance are available.
It is essential to respect the individual’s right to autonomy
and knowledge, while guaranteeing protection of privacy
where necessary. This is because the products can the-
oretically be used for disguised paternity or for prenatal
tests. In these cases the highest priority is the protection of
people who lack legal capacity, such as children. Quality
control and data security also pose a certain problem: as the
analysis of DTC tests is done abroad, it is scarcely possible
to check the quality of the results and the security of the
data. Certification according to European or internationally
valid standards offers a certain degree of security.
However, a general prohibition of DTC tests in Switzerland
is also rendered unnecessary – simply because it cannot
be enforced internationally. In view of these considerations
and after thorough consultation, the Expert Commission on
Human Genetic Testing (ECHGT) commissioned by the
Federal Office of Public Health (FOPH) opted for a cau-
tious opening up to DTC tests (see ECHGT recommend-
ations on revision of the Federal Law on Human Genetic
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Testing, March 2013). The Commission does, however, re-
commend banning such tests if they involve children, for
prenatal testing and without a person’s consent. It also re-
commends making the person ordering the test liable.
Challenge of a mountain of data
Another major challenge is the huge amount of data that is
essentially generated by these technological advances, es-
pecially by NGS. Thanks to NGS, large areas of the gen-
ome or exome can now be analysed simultaneously, then
interpreted. The advantage is that tests do not have to be
conducted consecutively, which is costly and time-consum-
ing. On the other hand, there is a greater probability of
incidental findings; hence information that was not even
being sought and the patient probably would not wish to
know at all. Should the doctor tell the patient about this
information? Only in the case of very serious diagnoses?
Or not even then? The person having a test done must be
aware beforehand what information might be delivered by
such a test and know what he/she does and does not want
to be told [2].
Large quantities of data in themselves do not signify a real
gain in knowledge. It is only the quality of interpretation
that creates added medical value. Achieving this requires
a high level of expertise and – in contrast to data collec-
tion – it remains complex and expensive. Experts agree
that the interpretation of genetic data cannot yet keep pace
with data collection. Meanwhile the ever-increasing flood
of data does not help to simplify data interpretation. At the
same time, experts stress that – as well as improvements
in the accuracy and speed of data analysis – defined qual-
ity criteria must be worked out for reliable interpretation
of results. High-throughput sequencing of lots of genes is
expected to detect thousands of new variants in the pa-
tients being tested. To minimise uncertainties and fears
about unclear clinical relevance, approaches need to be val-
idated which will enable benign polymorphisms to be dis-
tinguished from potentially pathogenic sequence changes.
Differences currently exist between provider laboratories
in this respect. Everyone agrees that, as well as solid exper-
ience, databases containing very high numbers of cases are
required to guarantee reliable results.
A good example of the challenge posed by data interpreta-
tion is evident from the requirement to make databases of
biomedical companies public. Many of the companies in
Switzerland and abroad have extensive databases built up
over a number of years. For instance, a company working
in this field over the past twenty years has developed one
of the largest databases for the analysis of the BRCA1 and
BRCA2 genes, recording all the sequence changes to the
relevant genes that have been diagnosed in patients. This
allows reliable statements to be made about the clinical rel-
evance of most of the variants in these genes [3]. The re-
quirement to make these databases public or at least share
them only makes sense superficially. This is because the
data merely form the foundation for what is actually the de-
cisive element in genetic testing, namely the reliable inter-
pretation of the data based on very large numbers of cases.
Data security is also a key issue. Companies’ genetic data-
bases contain sensitive data because they hold highly per-
sonal patient details, such as the data found in cancer re-
gisters (cancer diagnoses). If data were to be made public,
any residual risk of inferring the identity of the person con-
cerned would have to be entirely ruled out [4, 5].
Good data quality is expensive
Furthermore it is a matter of investment: building up a data-
base is a costly business. Constant maintenance is required
to guarantee superior data quality in the long term. On a
daily basis, new data sets are generated and identified
changes may have to be re-assessed. Doctors and those af-
fected may also be informed of any reclassification via sup-
plementary reports even years after the testing took place.
This contrasts with public databases (e.g. BIC, LOVID,
ENIGMA) which are not always updated regularly. Users of
such databases run the risk of relying on obsolete data. Over
the years, the cost of maintenance and updating a large data-
base can add up to substantial amounts of money. Compan-
ies make these investments because good data are the basis
for high quality and hence for business growth [6].
These challenges need to be tackled so that the population
can benefit to the utmost from the opportunities offered by
these developments: rapidly available and informative tests
for targeted therapies based on high quality data.
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